Carl Clay

ASOFormer: a Transformer-based model for predicting antisense oligonucleotide efficacy to support therapeutic candidate prioritization

Antisense oligonucleotides (ASOs) represent a promising therapeutic modality for RNA-based disease mechanisms, but identifying high-efficacy candidates from large sequence spaces remains a major bottleneck in drug development. Here, we present ASOFormer, a novel Transformer-based neural network that predicts the inhibi...